Filing Flows › vTv Therapeutics (VTVT) › Q1 2026
vTv Therapeutics (VTVT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
vTv Therapeutics (VTVT) reported revenue of $36.8M for the first quarter 2026 (Q1 2026). Operating margin was 63.1%, net earnings $24.1M (65.5% of revenue).
vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%, net earnings $24.1M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $36.8M | — | — |
| Operating profit | $23.3M | — | — |
| Net earnings | $24.1M | — | — |
| Operating cash flow | $9.2M | — | — |
What changed
Revenue was $36.8M in Q1 2026.
Operating profit was $23.3M, a 63.1% margin. Net earnings were $24.1M. The effective tax rate was 0.0%.
Operating cash flow was $9.2M, 38% of net earnings. Non-cash charges added back $1K of depreciation and $1.4M of share-based compensation. Working capital and other items used $16.4M.
Questions
What was vTv Therapeutics' revenue in the first quarter 2026?
vTv Therapeutics (VTVT) reported revenue of $36.8M for the first quarter 2026 (Q1 2026).
Was vTv Therapeutics profitable in the first quarter 2026?
Operating profit was $23.3M (63.1% of revenue) and net earnings $24.1M.
Source: vTv Therapeutics 10-Q on SEC EDGAR.